Placebo (n=13) | Tocilizumab (n=13) | |
Age, years | 55.5 (17.9) | 51.3 (20.3) |
Female, n (%) | 10 (76.9) | 10 (76.9) |
Disease duration*, years | 0.1 (0.0–10.8) | 0.5 (0.1–23.8) |
Body weight, kg | 53.8 (9.9) | 56.1 (9.6) |
Swollen joint count | 5.7 (3.3) | 4.2 (2.7) |
Tender joint count | 5.5 (3.3) | 4.2 (3.6) |
Patient pain VAS, mm | 37.2 (26.3) | 33.8 (30.2) |
Patient global VAS, mm | 44.5 (29.2) | 33.7 (28.8) |
Physician global VAS, mm | 42.3 (20.1) | 38.4 (24.5) |
HAQ–DI | 1.0 (1.0) | 0.7 (0.9) |
CRP, mg/dL | 4.7 (4.5) | 4.2 (4.1) |
Ferritin, ng/mL | 3869 (6272) | 2920 (1376) |
SFS | 5.1 (1.4) | 4.6 (1.7) |
Fever, n (%) | 6 (46.2) | 6 (46.2) |
Skin rash, n (%) | 7 (53.8) | 8 (61.5) |
ANA positivity, n (%) | 5 (38.5) | 8 (61.5) |
RF positivity, n (%) | 0 (0.0) | 1 (7.7) |
Anti-CCP positivity, n (%) | 0 (0.0) | 0 (0.0) |
PSL dose, mg/day | 32.5 (20.4) | 23.0 (16.2) |
Data are mean (SD) unless otherwise stated.
*Median (IQR).
ANA, antinuclear antibody; CRP, C reactive protein; HAQ–DI, Health Assessment Questionnaire Disability Index; PSL, prednisolone; RF, rheumatoid factor;SFS, systemic feature score; VAS, Visual Analogue Scale;anti-CCP, anticyclic citrullinated peptide antibody.